BR112015000349A2 - método de tratamento de tumores estromais gastrointestinais - Google Patents
método de tratamento de tumores estromais gastrointestinaisInfo
- Publication number
- BR112015000349A2 BR112015000349A2 BR112015000349A BR112015000349A BR112015000349A2 BR 112015000349 A2 BR112015000349 A2 BR 112015000349A2 BR 112015000349 A BR112015000349 A BR 112015000349A BR 112015000349 A BR112015000349 A BR 112015000349A BR 112015000349 A2 BR112015000349 A2 BR 112015000349A2
- Authority
- BR
- Brazil
- Prior art keywords
- gastrointestinal stromal
- stromal tumors
- treatment
- inhibitor
- imatinib
- Prior art date
Links
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 title abstract 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 2
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 2
- 229960002411 imatinib Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 abstract 1
- 229960001796 sunitinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670168P | 2012-07-11 | 2012-07-11 | |
| PCT/US2012/061535 WO2013063003A1 (en) | 2011-10-28 | 2012-10-24 | Method of treating gastrointestinal stromal tumors |
| PCT/US2013/036273 WO2014011284A1 (en) | 2012-07-11 | 2013-04-12 | Method of treating gastrointestinal stromal tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015000349A2 true BR112015000349A2 (pt) | 2017-06-27 |
Family
ID=49916465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000349A BR112015000349A2 (pt) | 2012-07-11 | 2013-04-12 | método de tratamento de tumores estromais gastrointestinais |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150202203A1 (https=) |
| EP (1) | EP2872142A1 (https=) |
| JP (1) | JP2015522070A (https=) |
| KR (1) | KR20150036014A (https=) |
| CN (1) | CN104427986A (https=) |
| AU (1) | AU2013289175A1 (https=) |
| BR (1) | BR112015000349A2 (https=) |
| CA (1) | CA2878251A1 (https=) |
| IN (1) | IN2014DN10801A (https=) |
| MX (1) | MX2015000457A (https=) |
| RU (1) | RU2015104537A (https=) |
| WO (1) | WO2014011284A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX382436B (es) * | 2016-01-11 | 2025-03-13 | Merck Patent Gmbh | Derivados de quinolin-2-ona. |
| EP3974340A1 (en) | 2017-05-05 | 2022-03-30 | CSP Technologies, Inc. | Container having child-resistant senior-friendly features |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US10835531B1 (en) * | 2019-06-18 | 2020-11-17 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220323412A1 (en) * | 2019-09-06 | 2022-10-13 | Chi-Chih Kang | Extracellular vesicle-fenretinide compositions, extracellular vesicle-c-kit inhibitor compositions, methods of making and uses thereof |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021154888A1 (en) | 2020-01-27 | 2021-08-05 | Mantra Bio. Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| DE60115069T2 (de) | 2000-09-11 | 2006-08-03 | Chiron Corp., Emeryville | Chinolinonderivate als tyrosin-kinase inhibitoren |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| US20050209247A1 (en) | 2003-11-07 | 2005-09-22 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1885187B1 (en) | 2005-05-13 | 2013-09-25 | Novartis AG | Methods for treating drug resistant cancer |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| NZ567550A (en) | 2005-11-29 | 2011-08-26 | Novartis Ag | Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one |
| EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| ES2554513T3 (es) | 2008-05-23 | 2015-12-21 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| RU2014120792A (ru) * | 2011-10-28 | 2015-12-10 | Новартис Аг | Способ лечения стромальных опухолей желудочно-кишечного тракта |
-
2013
- 2013-04-12 IN IN10801DEN2014 patent/IN2014DN10801A/en unknown
- 2013-04-12 AU AU2013289175A patent/AU2013289175A1/en not_active Abandoned
- 2013-04-12 BR BR112015000349A patent/BR112015000349A2/pt not_active IP Right Cessation
- 2013-04-12 CA CA 2878251 patent/CA2878251A1/en not_active Abandoned
- 2013-04-12 EP EP13718720.9A patent/EP2872142A1/en not_active Withdrawn
- 2013-04-12 CN CN201380037065.7A patent/CN104427986A/zh active Pending
- 2013-04-12 WO PCT/US2013/036273 patent/WO2014011284A1/en not_active Ceased
- 2013-04-12 KR KR20157000335A patent/KR20150036014A/ko not_active Withdrawn
- 2013-04-12 US US14/413,045 patent/US20150202203A1/en not_active Abandoned
- 2013-04-12 RU RU2015104537A patent/RU2015104537A/ru unknown
- 2013-04-12 JP JP2015521607A patent/JP2015522070A/ja active Pending
- 2013-04-12 MX MX2015000457A patent/MX2015000457A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014011284A1 (en) | 2014-01-16 |
| CN104427986A (zh) | 2015-03-18 |
| IN2014DN10801A (https=) | 2015-09-04 |
| RU2015104537A (ru) | 2016-08-27 |
| MX2015000457A (es) | 2015-04-08 |
| CA2878251A1 (en) | 2014-01-16 |
| KR20150036014A (ko) | 2015-04-07 |
| EP2872142A1 (en) | 2015-05-20 |
| AU2013289175A1 (en) | 2015-01-22 |
| JP2015522070A (ja) | 2015-08-03 |
| US20150202203A1 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000349A2 (pt) | método de tratamento de tumores estromais gastrointestinais | |
| BR112014009993A2 (pt) | método para o tratamento de tumores do estroma gastrointestinal | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
| EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| IN2015DN00438A (https=) | ||
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| MX2014011117A (es) | Tratamiento de cancer con inhibidores de tor cinasa. | |
| IN2014CN03597A (https=) | ||
| MX357502B (es) | Derivados de pirrolotriazinona. | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| MA32400B1 (fr) | Isoquinoléines et isoquinolinones substituées en tant qu'inhibiteurs de rho-kinase | |
| EA201492279A1 (ru) | Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек | |
| EA201170294A1 (ru) | Способы лечения реперфузионных повреждений | |
| EA201291329A1 (ru) | Гетероциклические соединения, их получение и их терапевтическое применение | |
| PH12014501534A1 (en) | Inhibitors of iap | |
| EA201170447A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
| BR112013033836A2 (pt) | terapia de combinação | |
| EA201001362A1 (ru) | Хинолины в качестве ингибиторов фарнезилпирофосфатсинтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |